Affimed to Report First Quarter 2021 Financial Results & Corporate Update July 1, 2021GlobeNewsWire • 06/22/21
Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical StudiesBenzinga • 05/14/21
Affimed Announces Publication of Preclinical Data in Clinical Cancer Research Supporting Therapeutic Potential of AFM13 in Combination with Natural Killer CellsGlobeNewsWire • 05/13/21
Affimed N.V. (AFMD) CEO Adi Hoess on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 04/15/21
Affimed Reports 2020 Financial Results and Highlights Recent Operational ProgressGlobeNewsWire • 04/15/21
Affimed Highlights the Potential of its Innate Cell Engager AFM24 as EGFR-targeting Therapy for Solid Tumors as Monotherapy and in Combination with Adoptive NK Cell Transfer at AACR Virtual Annual Meeting IGlobeNewsWire • 04/12/21
Affimed Stock Jumps After Natural Killer Cells With AFM13 Show Clinical Responses, Minimal ToxicityBenzinga • 04/09/21
Affimed Announces Presentation at AACR Highlighting Initial Data from Phase 1 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13GlobeNewsWire • 04/09/21
Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021GlobeNewsWire • 04/08/21
5 Small-Cap Biotech Stocks Trading Under $10 With Massive Upside Potential24/7 Wall Street • 04/03/21
Affimed and NKMax America Announce FDA Clearance of IND Application to Study the Combination of AFM24, an EGFR Targeted Innate Cell Engager, with SNK-01 Natural Killer Cell Therapy in Solid TumorsGlobeNewsWire • 03/31/21
Affimed To Continue Enrollment In AFM13 Lymphoma Study After Positive Interim DataBenzinga • 03/10/21
Affimed Announces Continuation of REDIRECT, a Registration-directed Study of AFM13 in PTCL, after Positive Preplanned Interim Futility AnalysisGlobeNewsWire • 03/10/21